Premium
Morbilliform drug eruption due to pegylated α‐interferon can show complete regression after switching to non‐pegylated interferon
Author(s) -
BARUT Sener,
YUKSEK Jale,
SEZER Engin,
GUNAL Ozgur,
KOSEOGLU Dogan
Publication year - 2011
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2010.01088.x
Subject(s) - pegylated interferon , medicine , drug eruption , chronic hepatitis , interferon , dermatology , drug , pharmacology , immunology , ribavirin , virus
Pegylated or non‐pegylated α‐interferon are frequently used medications for the treatment of both chronic hepatitis B and chronic hepatitis C. Skin disorders, which are mainly comprised of eczematous dermatitis, are frequently seen during treatment with this drug. However, drug eruption or morbilliform eruptions due to interferons have been rarely reported so far. We herein describe a patient who developed morbilliform drug eruption under treatment with pegylated interferon. She was able to continue treatment after switching from pegylated interferon to conventional interferon.